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OBJECTIVES: To analyze quantitative changes in glaucoma
treatment strategies between 1997 and 2003 in France.
METHODS: The number of trabeculectomies and other glau-
coma surgeries was extracted from the national database of the
French Diagnosis Related Group system, which includes data for
both public and private hospitals. Numbers of patients treated
per year were estimated from drug unit sales using deﬁned daily
doses for each drug. RESULTS: New medical treatments of glau-
coma and ocular hypertension, introduced in France between
1997 and 2003, allowed to treat 557,000 patients. In 2003, 63%
of patients treated with these new medicines were receiving
prostaglandins (39% latanoprost, 9% travoprost, 8% the ﬁxed
combination of latanoprost + timolol, and 7% bimatoprost), 13%
brinzolamide, 13% the ﬁxed combination of dorzolamide +
timolol and 11% brimonidine. During the same period, tra-
beculectomies declined by 38% (−48% in public hospitals and 
−32% in private clinics), while the total number of glaucoma surg-
eries declined by 22% (−34% in public hospitals and −14% in
private clinics). Hospital days related to open-angle glaucoma
surgery declined by 51%. There is a strong correlation (r = −0.97)
between the reduction of glaucoma surgery and the increase in
the number of patients treated with prostaglandins during the
study period. CONCLUSIONS: Between 1997 and 2003, new
glaucoma drugs, primarily prostaglandins, by improving IOP
control and stabilizing disease progression in many patients, may
have delay surgery, reducing glaucoma surgery by 22%.
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OBJECTIVES: Glaucoma is an optic neuropathy associated with
visual ﬁeld loss. Uncontrolled disease may progress to total
blindness. Currently, the only treatment for glaucoma is to lower
intraocular pressure. First-line treatment involves using β-
blockers or prostaglandin analogs. β-blockers and other intraoc-
ular pressure lowering agents may be used as adjunctive therapy
to prostaglandins. We quantiﬁed the use of adjunctive therapy
in association with prostaglandins. METHODS: We conducted
a cohort study using claims data from Québec, Canada. We iden-
tiﬁed all patients with a ﬁrst claim for bimatoprost, latanoprost
or travoprost between May 24, 2003 and February 28, 2005,
and analyzed adjunctive therapy utilization in the ﬁrst 12 months
of prostaglandin use. Use of adjunctive therapy was identiﬁed 
by at least two intermittent claims other than the index
prostaglandin in the 12-month follow-up period from their ﬁrst
prostaglandin prescription. Statistical and descriptive analyses
were performed using SAS 9.1. RESULTS: In total, 7982 patients
were included. The average age was 74 (±10) years, 60% were
females. Prostaglandin users who were naïve to any glaucoma
treatment, i.e. who started their therapy with prostaglandins,
comprised 60%, 58%, and 57% of the bimatoprost, latanoprost
and travoprost cohorts, respectively (no signiﬁcant differences,
χ2 = 1.20, p = 0.550). The proportions of patients requiring
adjunctive therapy were 40%, 35%, and 33% for bimatoprost,
latanoprost and travoprost, respectively. A signiﬁcantly higher
proportion of adjunctive therapy was associated with bimato-
prost users (bimatoprost vs. latanoprost: χ2 = 11.33, p < 0.001;
bimatoprost vs. travoprost: χ2 = 10.94, p < 0.001). CONCLU-
SIONS: Between 33% and 40% of continuous prostaglandin
users required adjunctive therapy in the ﬁrst 12 months. The
travoprost cohort had the lowest percentage of patients who
required adjunctive therapy. Further research is warranted for
incident vs. prevalent analyses, as well as economic impact.
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OBJECTIVE: To develop an approach to measuring current use
of topical ocular hypotensive medication that accounts for both
persistence (continuous use) and discontinuation followed by
restarting therapy. METHODS: This retrospective cohort study
of pharmacy claims submitted to a large national U.S. adminis-
trative claims database, analyzed claims for 3 prostaglandin ana-
logues (bimatoprost, latanoprost, and travoprost [index
prostaglandin]) submitted between 2001 and 2002. Patients who
did not have coverage in the plan for the preceding 180 days or
had been prescribed any ocular prostaglandin in the prior 180
days were excluded. Persistence was deﬁned as neither discon-
tinuing nor changing the index prostaglandin. The number of
current users of the index prostaglandin at day 180 was the sum
of patients who persisted with the index prostaglandin plus
patients who restarted the index prostaglandin following a dis-
continuation. RESULTS: Of the 4356 patients who started
prostaglandin therapy, 2503 (57%) were potential current 
users (were still plan members and had not switched ocular
hypotensive therapies after 180 days). Just over half of these,
(1356/2503, 54%) were actual current users, including 879/2503
(35%) who persisted with their index prostaglandin and
477/2503 (19%) who restarted their index prostaglandin. More
than half of those who discontinued their index prostaglandin
failed to restart any topical therapy (827/1624, 51%) before the
end of the study or their plan enrollment. CONCLUSIONS: Pre-
vious studies showing poor persistence for ocular hypotensive
therapy have not accounted for restarts. Including patients who
discontinue and restart therapy reﬂects current use more accu-
rately, but persistence remains a challenge.
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OBJECTIVES: Limited research has been conducted to evaluate
the humanistic and economic burden of age-related macular
degeneration (AMD). A multi-country, cross-sectional study was
conducted to examine the burden of bilateral neovascular AMD
(NV-AMD) on visual impairment, quality of life (QOL), and
vision-related functioning (VF), and explore the relationship
among these outcomes. METHODS: We surveyed 401 bilateral
NV-AMD patients recruited from retina specialists and 471
elderly non-AMD (control) patients from general practitioners in
France, Germany, Spain, UK and Canada. Patients completed a
telephone survey including a set of validated instruments: the
National Eye Institute Visual Function Questionnaire (NEI VFQ-
25), the EuroQol (EQ-5D), and the Hospital Anxiety and Depres-
sion Scale (HADS). Physicians recorded visual acuity (VA) and
treatment information. Multivariate regression models were uti-
lized in the analysis. RESULTS: Based on their better eye VA, NV-
AMD patients were categorized as having normal VA (>20/40,
13%), mildly impaired VA (20/40 to >20/80, 21%), moderately
impaired VA (20/80 to >20/200, 28%), severely impaired VA
(20/200 to >20/400, 18%), and near blindness (<20/400, 19%).
They reported a decremental mean VF (NEI VFQ summary scale
score) from 62.4 (normal VA) to 39.4 (near blindness) and an
incremental mean depression symptom (HADS depression sub-
scale score) from 5.5 (normal VA) to 8.5 (near blindness) (p <
0.001), while control subjects (all with better eye normal VA)
reported substantially better VF (mean NEI VFQ score of 89.1)
and fewer depression symptoms (mean HADS depression score
of 4.1). However, no discernable trend was observed in EQ-5D
(a general QOL measure) or HADS anxiety subscale scores across
VA impairment level. CONCLUSIONS: Vision-speciﬁc QOL
measures are important in capturing the relationship between
vision loss and QOL in NV-AMD patients. Consistent with the
literature, greater depression symptoms and lower VF were
observed in AMD patients with more severe vision loss.
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OBJECTIVES: Latanoprost, a prostaglandin inhibitor, is being
increasingly used in therapeutic management of glaucoma.
However, scant literature exists examining the cost and outcomes
ramiﬁcations of latanoprost. This study examined the medica-
tion use behavior (medication related adherence and persistence
rates) and costs associated with the introduction of latanoprost
therapy in an older population (aged 65 and above) enrolled in
Medicare. METHODS: The study employed a retrospective
observational cohort design and used administrative claims data
from a Medicare HMO, which offered complete coverage to
enrollees, including prescription beneﬁt. The case group con-
sisted of 100 patients with glaucoma who began latanoprost
therapy. The control group consisted of 168 enrollees with glau-
coma, and who started any other therapy other than latanoprost.
Both groups were followed for one year before and after initia-
tion of therapy. Bivariate and multivariate techniques incorpo-
rating health care utilization in the year prior to start of new
therapy were utilized to determine the study outcomes.
RESULTS: Introduction of latanoprost therapy was associated
with signiﬁcantly higher medication persistence and adherence
rates as compared to patients starting any other glaucoma med-
ication (p < 0.01). Further, there were no additional increases in
total health care costs in the entire population associated with
the introduction of latanoprost therapy, after adjusting for group
and time effects, as well as other confounders (p > 0.05). CON-
CLUSIONS: Latanoprost therapy offered improved medication
use behavior in older adults with glaucoma and did not increase
overall health care costs in this population. Long-term manage-
ment with latanoprost therapy may offer signiﬁcant costs-savings
for glaucoma patients.
PEY23
VISION WITH RESTOR® VERSUS MONOFOCAL
INTRAOCULAR LENSES (IOL) AFTER CATARACT SURGERY:
RESULTS OF A POOLED ANALYSIS
Berdeaux G1,Viala M2,Arnould B2
1Alcon France, Rueil-Malmaison, France, 2Mapi Values France, Lyon,
France
OBJECTIVE: Multifocal IOLs are a new development to restore
distance and near vision after cataract surgery and liberate
patients from spectacles. The following analysis compares vision
beneﬁts reported by patients after ReSTOR® versus monofocal
IOL implants. METHODS: Data were pooled from two clinical
trials conducted in Europe and the United States in patients
undergoing cataract surgery. A total of 499 patients were
implanted with ReSTOR®, a multifocal IOL, and 173 patients
with a monofocal IOL (MoF). Patients self-reported vision on
the well validated TyPE outcome questionnaire, comprising 67
items assessing all aspects of visual function, with and without
spectacles, including distance and near vision. The TyPE was
administered three-times: at baseline, after ﬁrst-eye (EYE1)
surgery, and following second-eye surgery (EYE2). A clinically
signiﬁcant TyPE response was deﬁned as a change from baseline
greater than one-half the baseline score standard deviation.
Cumulative response curves of the IOL groups were compared
by a Kolmogorov-Smirnov (KS) test. RESULTS: Distance vision
improved equally after ReSTOR® and MoF, with and without
spectacles. However, near vision after EYE1 improved more fre-
quently (p < 0.0001) with ReSTOR® (75%) than MoF (57%),
and improved even more after EYE2 (p < 0.0001): ReSTOR®
(88%) versus MoF (62%). KS tests conﬁrmed the superiority of
ReSTOR® over MoF (p < 0.0001). The improvement of near
vision without spectacles in the ReSTOR® group was equivalent
to that with spectacles in the MoF group. CONCLUSIONS:
ReSTOR® improves both distance and near vision, and allows
most patients to abandon spectacles.
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OBJECTIVES: The MacDQoL showed good metric properties in
previous UK work. The aim of this survey was to conﬁrm these
results in other countries and explore possibilities of subscales.
METHODS: Two clinical trials were pooled (France 120;
Germany 126, Italy 139; USA 412). Principal component analy-
ses (Varimax) was conducted on baseline data from separate coun-
tries. Factorial structures were compared between countries and
Cronbach’s alpha curves were used to identify subscale scores.
Four groups of patients were identiﬁed according to visual acuity
(VA) in their best eye (BE < 5/10; BE >= 5/10) and worst eye (WE
< 1/10; WE >= 1/10) and were used to investigate (ANOVA) the
sensitivity of MacDQoL to VA and compare with the NEI-VFQ-
